<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-5129-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RAFLOX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alrai Pharmaceutical industry Co. (L.L.C)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        S01AX19 
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>RAFLOX film coated tablet contain a medicine called levofloxacin which belongs to an antibiotics group called &quot;quinolone&quot;. It works by killing the bacteria that cause infections in your body. Used in adults 18 years or older.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Therapeutic indications:</strong></p><p>RAFLOX tablets can be used to treat infections of the:</p><p>&middot;&nbsp; Nasal sinuses.</p><p>&middot;&nbsp; Lungs, in people with long-term breathing problems or pneumonia.</p><p>&middot; Urinary tract, including your kidneys or bladder.</p><p>&middot; Prostate gland, where you have a long lasting infection.</p><p>&middot; Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;.</p><p>In some special situations, RAFLOX may be used to lessen the chances of getting a pulmonary disease named anthrax or worsening of the disease after you are exposed to the bacteria causing anthrax.</p><p>Sometimes infections are caused by viruses rather than by bacteria. Example include viral infections in the sinuses and lungs, such as the common cold or flu. Antibiotics, including RAFLOX, do not kill viruses.</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>A. Do not take this medicine and tell your doctor if:</strong></p><p>&middot; You are allergic to levofloxacin, or any other quinolone antibiotic such as moxifloxacin, ciprofloxacin or ofloxacin or any of the other ingredients of RAFLOX tablets (listed in section 6 below). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&middot; You have ever had epilepsy.</p><p>&middot; You have ever had a problem with your tendons such as tendonitis that was related to treatment with a &lsquo;quinolone antibiotic&rsquo;.</p><p>&middot; You are a child or a growing teenager.</p><p>&middot; You are pregnant, might become pregnant or think you may be pregnant.</p><p>&middot; You are breast-feeding.</p><p>&middot; If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately.</p><p><strong>Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking RAFLOX tablets.</strong></p><p><strong>B. Warnings and precaution:</strong></p><p><strong>Talk to your doctor or pharmacist before taking RAFLOX if:</strong></p><p>&middot;&nbsp;You are 60 years of age or older.</p><p>&middot;&nbsp; You are using corticosteroids, sometimes called steroids (see section &ldquo;Other medicines and RAFLOX&rdquo;).</p><p>&middot; You have ever had a fit (seizure).</p><p>&middot; You have had damage to your brain due to a stroke or other brain injury.</p><p>&middot; You have kidney problems.</p><p>&middot; You have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. You are more likely to have serious problems with your blood when taking this medicine.</p><p>&middot; You have ever had mental health problems.</p><p>&middot; You have ever had Heart problems: Caution should be taken when using RAFLOX, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section Other medicines and RAFLOX).</p><p>&middot;&nbsp; If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</p><p>&middot; If you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, high blood pressure, or atherosclerosis).</p><p>&middot; You are diabetic.</p><p>&middot; You have ever had liver problems.</p><p>&middot;&nbsp; You have myasthenia gravis.</p><p>&middot; If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.</p><p><strong>Other warnings:</strong></p><p>&middot; RAFLOX may rarely cause pain and inflammation in tendons. Particularly if you are elderly or taking steroid medicines (such as cortisone or hydrocortisone). If you have any problems with your tendons whilst or shortly after taking RAFLOX, seek medical advice at once and rest the affected limb (leg or arm). Do not take the next dose of RAFLOX unless your doctor tells you to. In such as cases, you experience swelling or pain in the area of affected tendon. It may be necessary to stop treatment</p><p>&middot; If you start having severe, persistent and/or bloody diarrhea during or after treatment with RAFLOX, tell your doctor immediately. This could mean you have serious inflammation of your bowel (pseudomembranous colitis), which can sometimes occur after antibiotic treatment. You may need to stop taking levofloxacin and your doctor may give you another medicine.</p><p>&middot;&nbsp; Whilst taking RAFLOX you are advised to stay out of strong sunlight. This is because some patients may become more sensitive to light whilst taking RAFLOX and get a sun-burn like reaction.</p><p>&middot; RAFLOX should be discontinued if the patient experiences symptoms Burning, tingling, pain or numbness. These may be signs of something called &lsquo;neuropathy&rsquo;.</p><p>&middot; RAFLOX is not an optimal therapy for most severe cases of Pneumococcal pneumonia.</p><p>&middot;&nbsp; Infections got from a hospital during treatment due to P.aeruginosa may require combination therapy.</p><p>&middot; RAFLOX is not effective against infections caused by MRSA. In infections suspicious for MRSA levofloxacin should be combined with an agent approved to treat MRSA infections.</p><p><strong>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking RAFLOX.</strong></p><p><strong>C. Other medicines and RAFLOX:</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including those obtained without a prescription.</p><p><strong>In particular, tell your doctor if you are taking any of the following medicines. This is because it can increase the chance of you getting side effects, when taken with RAFLOX tablets:</strong></p><p>&middot; Corticosteroids: used for inflammation. You may be more likely to have inflammation and/or rupture of your tendons.</p><p>&middot;&nbsp;Warfarin: used to thin the blood. You may be more likely to have a bleed. Your doctor may need to take regular blood tests to check how well your blood can clot.</p><p>&middot; Theophylline: used for breathing problems. You are more likely to have a fit (seizure) if taken with RAFLOX.</p><p>&middot; Non-steroidal anti-inflammatory drugs (NSAIDS): used for pain and inflammation such as aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a fit (seizure) if taken with RAFLOX.</p><p>&middot; Ciclosporin: used after organ transplants. You may be more likely to get the side effects of Ciclosporin.</p><p>&middot; Medicines known to affect the way your heart beats: This includes medicines used for abnormal heart rhythm (antiarrhythmics such as quinidine and amiodarone), Tricyclic antidepressants (such as amitriptyline and imipramine), Macrolide antibiotics (such as erythromycin, azithromycin and clarithromycin) and Anti-psychotic medicines.</p><p>&middot; Probenecid (used for gout) and Cimetidine (used for ulcers and heartburn).</p><p><strong>Do not take RAFLOX tablets at the same time as the following medicines. Either 2 hours before or 2 hours after taking these products:</strong></p><p>&middot; Iron tablets (for anemia), multivitamin, or other product that has magnesium, aluminum, iron or zinc.</p><p>&middot; Magnesium or aluminum-containing antacids (for acid or heartburn).</p><p>&middot; Sucralfate (for stomach ulcers).</p><p>&middot; Didanosine antiviral drug for HIV.</p><p>This is because it can affect the way RAFLOX tablets work.</p><p><strong>Urine tests for opiates:</strong></p><p>Urine tests may show &lsquo;false positive&rsquo; results for strong painkillers called &lsquo;opiates in people taking RAFLOX (levofloxacin) tablets. If your doctor is due to take a urine test, tell him you are taking RAFLOX tablets.</p><p><strong>Tuberculosis tests:</strong></p><p>This medicine may cause &ldquo;false negative&rdquo; results for some tests used in laboratory to search for the bacteria causing tuberculosis.</p><p><strong>Taking RAFLOX with food and drink:</strong></p><p>Take without regard to meals. Take with plenty of water. Taking this product with orange juice can result in reduced quinolone plasma levels.</p><p><strong>D. Pregnancy and breast-feeding:</strong></p><p>If you are pregnant or breast-feeding, think you may be a pregnant or planning to have a baby ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>E. Driving and using machines:</strong></p><p>You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being able to concentrate and your reaction speed. If this happens, do not drive or carry out any work that requires a high level of attention.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take RAFLOX tablets exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&bull; Take this medicine by mouth</p><p>&bull; Swallow the tablets whole with a drink of water</p><p>&bull; The tablets may be taken during meals or at any time between meals</p><p><strong>Protect your skin from sunlight</strong></p><p>Keep out of direct sunlight while taking this medicine and for 2 days after you stop taking it. This is because your skin will become much more sensitive to the sun and may burn, tingle or severely blister if you do not take the following precautions:</p><p>&bull; Make sure you use high factor sun cream.</p><p>&bull; Always wear a hat and clothes which cover your arms and legs.</p><p>&bull; Avoid sun beds.</p><p><strong>How much to take</strong></p><p>&bull; Your doctor will decide on how many RAFLOX film coated tablet you should take.</p><p>&bull; The dose will depend on the type of infection you have and where the infection is in your body.</p><p>&bull; The length of your treatment will depend on how serious your infection is.</p><p>&bull; If you feel the effect of your medicine is too weak or strong, do not change the dose by yourself, but ask your doctor.</p><p><strong>Adults and the elderly with normal renal function:</strong></p><p><strong>Sinuses infection:</strong></p><p>&bull; Two tablet of 250 mg once daily.</p><p>&bull; 500 mg, once daily.</p><p>&bull; 750 mg, once daily.</p><p><strong>Pneumonia:</strong></p><p>&bull; Two tablets of 250 mg, once or twice daily.</p><p>&bull; 500 mg, once daily.</p><p>&bull; 750 mg, once daily.</p><p><strong>Lungs infection, in people with long-term breathing problems:</strong></p><p>&bull; Two tablets of 250 mg, once daily.</p><p>&bull; One tablet of 500 mg, once daily.</p><p><strong>Urinary tract infection or acute pyelonephritis:</strong></p><p>&bull; 750 mg, once daily.</p><p><strong>Chronic bacterial prostatitis:</strong></p><p>&bull; 500 mg, once daily.</p><p><strong>Infection of skin and underneath the skin, including muscles:</strong></p><p>&bull; Two tablets of 250 mg, once or twice daily.</p><p>&bull; One tablet of 500 mg, once or twice daily.</p><p><strong>Adults with kidney problems:</strong></p><p>&bull; Your doctor may need to give you a lower dose.</p><p><strong>Children and Adolescence:</strong></p><p>&bull; RAFLOX must not be given to children or teenagers below 18 years.</p><p>That&rsquo;s because children have a higher chance of getting bone, joint, or tendon problems such as pain or swelling while taking RAFLOX.</p><p><strong>A. If you take more RAFLOX tablets than you should:</strong></p><p>If you accidentally take more tablets than you should, tell a doctor or get other medical advice straight away. Take the medicine pack with you. This is so the doctor knows what you have taken. The following effects may happen: convulsive fits (seizures), feeling confused, dizzy, less conscious, and heart problems leading to uneven heart beats as well as feeling sick (nausea).</p><p><strong>B. If you forget to take RAFLOX tablets:</strong></p><p>If you forgot to take your dose, take it as soon as you remember unless it is nearly time for your next dose. Do not double-up the next dose to make up for the missed dose.</p><p><strong>C. If you stop taking RAFLOX tablets:</strong></p><p>Do not stop taking RAFLOX just because you feel better. It is important that you complete the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too soon, the infection may return, your condition may get worse or the bacteria may become resistant to the medicine.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, RAFLOX can cause side effects, although not everybody gets them. These effects are normally mild or moderate and often disappear after a short time.</p><p><strong>Stop taking RAFLOX and see a doctor or go to a hospital straight away if you notice the following side effect:</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&bull; Watery diarrhea which may have blood in it, possibly with stomach cramps and a high temperature. These could be signs of a severe bowel problem.</p><p>&bull; Pain and inflammation in your tendons or ligaments, which could lead to rupture. The</p><p>Achilles tendon is affected most often.</p><p>&bull; Convulsions.</p><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><p>&bull; You have an allergic reaction. The signs may include: rash, swallowing or breathing problems, swelling of your lips, face, throat, or tongue.</p><p>&bull; Burning, tingling, pain or numbness. These may be signs of something called &lsquo;neuropathy&rsquo;.</p><p><strong>Other:</strong></p><p>&bull; Severe skin rashes which may include blistering or peeling of the skin around your lips, eyes, mouth, nose and genitals.</p><p>&bull; Loss of appetite, skin and eyes becoming yellow in color, dark-colored urine, itching, or tender stomach (abdomen). These may be signs of liver problems which may include a fatal failure of the liver.</p><p>If your eyesight becomes impaired or if you have any other eye disturbances whilst taking</p><p>RAFLOX and consult an eye specialist immediately.</p><p><strong>Tell your doctor if any of the following side effects gets serious or lasts longer than a few days:</strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&bull; Sleeping problems.</p><p>&bull; Headache, feeling dizzy.</p><p>&bull; Feeling sick (nausea, vomiting) and diarrhea.</p><p>&bull; Increase in the level of some liver enzymes in your blood.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&bull; Changes in the number of other bacteria or fungi, infection by fungi named Candida, which may need to be treated.</p><p>&bull; Changes in the number of white blood cells shown up in the results of some blood tests (leukopenia, eosinophilia).</p><p>&bull; Feeling stressed (anxiety), confused, nervous, sleepy, trembling, and a spinning (vertigo).</p><p>&bull; Shortness of breath (dyspnea).</p><p>&bull; Changes in the way things taste, loss of appetite, stomach upset or indigestion (dyspepsia), and feeling bloated (flatulence) or constipation.</p><p>&bull; Itching and skin rash, urticaria, sweating too much (hyperhidrosis).</p><p>&bull; Joint pain or muscle pain.</p><p>&bull; Blood tests may show unusual results due to liver (bilirubin increased) or kidney (creatinine increased) problems.</p><p>&bull; General weakness.</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&bull; Bruising and bleeding easily due to a lowering in the number of blood platelets (thrombocytopenia).</p><p>&bull; Low number of white blood cells (neutropenia).</p><p>&bull; Exaggerated immune response (hypersensitivity).</p><p>&bull; Lowering of your blood sugar levels (hypoglycaemia). This is important for people that have diabetes.</p><p>&bull; Hallucinations, paranoia, and change in your opinion and thoughts (psychotic reactions) with a risk of having suicidal thoughts or actions.</p><p>&bull; Feeling depressed, mental problems, feeling restless (agitation), or nightmares.</p><p>&bull; Tingly feeling in your hands and feet (paresthesia).</p><p>&bull; Problems with your hearing (tinnitus) or eyesight (blurred vision).</p><p>&bull; Unusual fast beating of your heart (tachycardia) or low blood pressure (hypotension).</p><p>&bull; Muscle weakness. This is important in people with myasthenia gravis (a rare<strong> </strong>disease of the nervous system).</p><p>&bull; Changes in the way your kidney works and occasional kidney failure which may be due to an allergic kidney reaction called interstitial nephritis.</p><p>&bull; Fever.</p><p><strong>Other side effects include:</strong></p><p>&bull; Anemia: this can make the skin pale or yellow due to damage of the red blood cells; lowering in the number of all types of blood cells (pancytopenia).</p><p>&bull; Fever, sore throat and a general feeling of being unwell that does not go away. This may be due to a lowering in the number of white blood cells (agranulocytosis).</p><p>&bull; Sudden drop in blood circulation (anaphylactic shock).</p><p>&bull; Increase of your blood sugar levels (hyperglycemia) or lowering of your blood sugar levels leading to coma (hypoglycemic coma). This is important for people that have diabetes.</p><p>&bull; Changes in the way things smell, loss of smell or taste.</p><p>&bull; Problems moving and walking (dyskinesia, extrapyramidal disorders).</p><p>&bull; Temporary loss of consciousness or posture (syncope).</p><p>&bull; Temporary loss of vision.</p><p>&bull; Impairment or loss of hearing.</p><p>&bull; Abnormal fast heart rhythm, life-threatening irregular heart rhythm including cardiac arrest, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart).</p><p>&bull; Difficulty breathing or wheezing (bronchospasm).</p><p>&bull; Allergic lung reactions.</p><p>&bull; Pancreatitis.</p><p>&bull; Inflammation of the liver (hepatitis).</p><p>&bull; Increased sensitivity of your skin to sun and ultraviolet light (photosensitivity).</p><p>&bull; Inflammation of the blood vessels due to an allergic reaction (vasculitis).</p><p>&bull; Inflammation of the tissue inside the mouth (stomatitis).</p><p>&bull; Muscle rupture and muscle destruction (rhabdomyolysis).</p><p>&bull; Joint redness and swelling (arthritis).</p><p>&bull; Pain, including pain in the back, chest and extremities.</p><p>&bull; Attacks of porphyria in people who already have porphyria (a very rare metabolic disease).</p><p>&bull; Persistent headache with or without blurred vision (benign intracranial hypertension).</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. </strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-205-7662</p><p>Call NPC at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8002490000</p><p>E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; npc.drug@sfda.gov.sa</p><p>Website: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;www.sfda.gov.sa/npc</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Keep RAFLOX film coated tablets in the original strips and box in a dry place.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the carton and foil after EXP. The expiry date refers to the last day of the month.</p><p>&bull; Don&rsquo;t store above 30&deg;C.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; RAFLOX 250 mg, 500 mg and 750 mg contains the active substance Levofloxacin Hemihydrate. Each tablet contains either 250 mg, 500 mg or 750 mg of levofloxacin.</p><p>&bull; The other ingredients are: microcrystalline cellulose, hypromellose, crospovidone, croscarmellose sodium, magnesium stearate and opadry white.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
• RAFLOX 250 mg is a white to off white film-coated tablet in the shape of a caplet and has "C7" marked on one side.

• RAFLOX 500 mg is a white to off white film-coated tablet in the shape of a caplet and has "C5" marked on one side.

• RAFLOX 750 mg is a white to off white film-coated tablet in the shape of a caplet and has "C6" marked on one side.

• RAFLOX 250 mg, 500 mg and 750 mg is available in blister packs containing 5 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Alrai Pharmaceutical Industries Co. (L.L.C.)</strong></p><p>Al Wadi - 2, Almu&rsquo;tasem Bellah Al Fatemy Street</p><p>P.O.Box: 9224 Jeddah - 21413 Kingdom of Saudi Arabia</p><p><u>Tel</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966 12 2888949</p><p><u>Fax</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966 12 2889014</p><p><u>E-mail:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; info@alraipharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص رافلوكس المغلفة غشائيا. على دواء يسمى ليفوفلوكساسين والذي يستخدم في علاج المرضى من 18 عاما فأكثر. وتنتمي مادة ليفوفلوكساسين لإحدى مجموعات المضادات الحيوية والتي تسمى الكوينولونات. وتعمل مادة الليفوفلوكساسين على قتل البكتيريا التي تسبب الأمراض المعدية في جسمك.</p><p dir="RTL"><strong>دواعي الاستخدام </strong></p><p dir="RTL">يمكن استخدام أقراص رافلوكس لعلاج التهابات:</p><p dir="RTL">- الجيوب الأنفية.</p><p dir="RTL">- الرئتين، في الأشخاص الذين يعانون من مشاكل تنفسية طويلة الأمد أو الذين يعانون من الالتهاب الرئوي.</p><p dir="RTL">- المسالك البولية، بما في ذلك الكليتين أو المثانة.</p><p dir="RTL">- غدة البروستاتا، في حالة حدوث العدوى طويلة الأمد.</p><p dir="RTL">- الجلد وتحت الجلد، بما في ذلك العضلات. تسمى أحيانا &quot;بالأنسجة الرخوة&quot;.</p><p dir="RTL">في بعض الحالات الخاصة، يمكن استخدام رافلوكس لتقليل فرص الإصابة بمرض رئوي يسمى الجمرة الخبيثة أو تفاقم المرض بعد التعرض للبكتيريا المسببة للجمرة الخبيثة.</p><p dir="RTL">أحيانا تكون العدوى ناجمة عن الفيروسات بدلا من البكتيريا، على سبيل المثال تشمل الالتهابات الفيروسية في الجيوب الأنفية والرئتين مثل نزلات البرد أو الانفلونزا.</p><p dir="RTL">المضادات الحيوية بما في ذلك رافلوكس لا تقتل الفيروسات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ.</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>واستشر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>إذا</strong><strong>:</strong></p><p dir="RTL">&bull; كان لديك فرط تحسس لمادة ليفوفلوكساسين أو لأي من المضادات الحيوية من مجموعة الكوينولونات مثل موكسيفلوكساسين ، سيبروفلوكساسين أوفلوكساسين أو لأي من مكونات أقراص رافلوكس &nbsp;(المذكورة في رقم 6) وتكون علامات فرط التحسس على هيئة طفح جلدي، مشاكل في البلع أو التنفس، وتورم في الشفتين، الوجه، الحلق أو اللسان.</p><p dir="RTL">&bull; كنت قد أصبت سابقا بمرض الصرع.</p><p dir="RTL">&nbsp;&bull;كانت لديك مشاكل بأوتار العضلات مثل التهاب الأوتار والمتعلقة باستخدام المضادات الحيوية التي تنتمي لمجموعة الكوينولونات.</p><p dir="RTL">&nbsp;&bull;كان المريض طفلا أو في مرحلة المراهقة.</p><p dir="RTL">&bull; كانت المريضة حامل أو من المحتمل أن تكون حاملاً.</p><p dir="RTL">&nbsp;&bull;كانت المريضة من الأمهات المرضعات.</p><p dir="RTL">&bull; إذا أصبح نظرك ضعيفًا أو شعرت بأن عينيك قد تأثرت ، استشر أخصائي العيون فورًا.<strong>&nbsp;</strong></p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>ألا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كانت</strong><strong> </strong><strong>تنطبق</strong><strong> </strong><strong>عليك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>النقاط</strong><strong> </strong><strong>المذكورة</strong><strong> </strong><strong>أعلاه</strong><strong>. </strong><strong>تحدث</strong><strong> </strong><strong>مع الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>رافلوكس</strong><strong> </strong><strong>في حالة إذا لم تكن متأكدا إذا كانت هذه الشروط تنطبق عليك أم لا. </strong></p><p dir="RTL"><strong>ب. التحذيرات والاحتياطات:</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك أو الصيدلي قبل تناول رافلوكس إذا:</strong></p><p dir="RTL">&bull; عمرك 60 سنة أو أكثر.</p><p dir="RTL">&bull; كنت تستخدم الكورتيكوستيرويدات، وتسمى أحياناً الستيرويدات (انظر القسم &quot;رافلوكس والأدوية والأخرى&quot;).</p><p dir="RTL">&bull; كان لديك في أي وقت مضى نوبة صرع.</p><p dir="RTL">&bull; حدث لديك سابقاً ضرراً بالمخ جراء سكتة دماغية أو أي إصابة أخرى بالمخ.</p><p dir="RTL">&bull; لديك مشاكل في الكلى.</p><p dir="RTL">&bull; كنت تعاني من نقص في انزيم نازعة هيدروجين الجلوكوز &ndash; 6 &ndash; فوسفات. فقد تكون أكثر عرضة لمشاكل خطيرة في الدم عند تناول هذا الدواء.</p><p dir="RTL">&bull; كنت تعاني من قبل من مشاكل نفسية أو عقلية.</p><p dir="RTL">&bull; حدث لديك من قبل مشاكل صحية في القلب : ينبغي توخي الحذر عند استخدام رافلوكس، إذا كنت قد ولدت مع أو لدى أحد أفراد أسرتك حالة تسمى إطالة فترة QT (يُرى في تخطيط القلب، تسجيل الكهربائية للقلب)، لديك اختلال في توازن الأملاح في الدم (وخاصة انخفاض مستوى البوتاسيوم أو المغنيسيوم في الدم)، لديك بطء في ضربات القلب، لديك فشل في القلب، أو حدث لك من قبل نوبات قلبية (احتشاء عضلة القلب)، إذا كنتِ أنثى او من كبار السن أو كنت تأخذ أدوية أخرى تؤدي إلى تغيرات غير طبيعية في تخطيط القلب (انظر القسم &quot;رافلوكس والأدوية الأخرى&quot;).</p><p dir="RTL">&bull; إذا حدث لديك سابقا تمزق بالشريان الأبهر (تمزق في جدار الأبهر).</p><p dir="RTL">&bull; إذا كان أحد من أفراد أسرتك يعاني من تمدد الأوعية الدموية الأبهري أو تمزق الأبهر أو عوامل أخرى قد تشكل خطر (مثل اضطرابات النسيج الضام كـ متلازمة مارفان، أو متلازمة إهلرز دانلوس الوعائية، أو اضطرابات الأوعية الدموية مثل التهاب الشريان تاكاياسو ، التهاب الشرايين الخلية العملاقة، مرض بهجت، ارتفاع ضغط الدم، أو تصلب الشرايين).</p><p dir="RTL">&bull; مُصاب بالسكري.</p><p dir="RTL">&bull; كُنت تعاني من مشاكل بالكبد.</p><p dir="RTL">&bull; كان لديك الوهن العضلي الوبيل.</p><p dir="RTL">&bull; إذا كنت تشعر بألم مفاجئ أو شديد في البطن أو الصدر أو الظهر، فانتقل على الفور إلى الطوارئ.</p><p dir="RTL"><strong>تحذيرات أخرى:</strong></p><p dir="RTL">&bull; رافلوكس قد يسبب نادرًا ألم والتهاب في الأوتار. لا سيما إذا كنت من كبار السن أو تأخذ أدوية الستيرويد (مثل الكورتيزون أو هيدروكورتيزون). إذا كان لديك أي مشاكل مع الأوتار في حين أو بعد فترة وجيزة من أخذ رافلوكس، اطلب المشورة الطبية وأرح الطرف المصاب (الساق أو الذراع). لا تأخذ الجرعة التالية من رافلوكس إلا إذا قال لك طبيبك. في مثل هذي الحالات، قد تعاني من تورم أو ألم في منطقة الأوتار المصابة. قد يكون من الضروري التوقف عن العلاج.</p><p dir="RTL">&bull; إذا بدأت تعاني من الإسهال الشديد والمستمر و/أو الدموي أثناء أو بعد العلاج بـ رافلوكس، فأخبر طبيبك على الفور. فهذا قد يعني أن لديك التهاب خطير في الأمعاء (التهاب القولون الكاذب)، والذي يمكن أن يحدث في بعض الأحيان بعد العلاج بالمضادات الحيوية. قد تحتاج إلى التوقف عن تناول رافلوكس وطبيبك قد يعطيك دواء آخر.</p><p dir="RTL">&bull; أثناء تناول رافلوكس ينصح لك البقاء بعيداً عن أشعة الشمس القوية. ويرجع ذلك إلى أن بعض المرضى قد يصبح أكثر حساسية للضوء عند أخذ رافلوكس والحصول على ردة فعل مثل حروق الشمس.</p><p dir="RTL">&bull; ينبغي التوقف عن أخذ رافلوكس إذا كان المريض يعاني من أعراض حرق، وخز، ألم أو تخدر. قد تكون هذه علامات تدل على شيء يسمى &quot;الاعتلال العصبي&quot;.</p><p dir="RTL">&bull; رافلوكس ليس العلاج الأمثل لمعظم الحالات الشديدة من الالتهاب الرئوي.</p><p dir="RTL">&bull; العدوى التي تحصل في المستشفى أثناء العلاج بسبب الزائفة الزنجارية قد تتطلب إضافة مضاد حيوي آخر.</p><p dir="RTL">&bull; رافلوكس ليس فعال ضد الالتهابات الناجمة عن المكورات العنقودية الذهبية المقاومـة للميثيسيلين. في العدوى المشبوهة بالمكورات العنقودية الذهبية المقاومـة للميثيسيلين ينبغي استخدام رافلوكس مع دواء مصرح لعلاج الالتهابات الناجمة بسبب المكورات العنقودية الذهبية المقاومـة للميثيسيلين.</p><p dir="RTL"><strong>إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي قبل تناول رافلوكس. </strong></p><p dir="RTL"><strong>ج. رافلوكس والأدوية الأخرى:</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ أو أخذت مؤخراً أي من الأدوية التي تحصل عليها دون وصفة طبية.</p><p dir="RTL"><strong>قم</strong><strong> </strong><strong>بإخبار</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>التالي</strong><strong> </strong><strong>ذكرها</strong><strong>. </strong><strong>وذلك</strong><strong> </strong><strong>نظراً لأن</strong><strong> </strong><strong>هذه الأدوية</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تزيد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>فرصة</strong><strong> </strong><strong>حدوث</strong><strong> </strong><strong>الاثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>تم</strong><strong> </strong><strong>تناولها</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>رافلوكس</strong><strong>:</strong></p><p dir="RTL">الكورتيكوستيرويدات: تستخدم في علاج الالتهاب. قد تزداد احتمالية اصابتك بالالتهاب و/أو حدوث تمزق بالأوتار.</p><p dir="RTL">&bull; الوارفارين: يستخدم لزيادة سيولة الدم. قد تكون أكثر عرضة للإصابة بالنزيف. قد يحتاج طبيبك إلى إجراء اختبارات دم منتظمة للتحقق من مدى تخثر الدم.</p><p dir="RTL">&bull; الثيوفيللين: يستخدم لمشاكل في التنفس. قد تزداد لديك القابلية لحدوث نوبات عصبية عند تناوله مع رافلوكس.</p><p dir="RTL">&bull; مضادات الالتهاب غير الستيرويدية: تستخدم للألم والالتهاب مثل الأسبرين، ايبوبروفين، فينبوفين، كيتوبروفين والإندوميثاسين. قد تزداد لديك القابلية لحدوث نوبات عصبية عند تناولها مع رافلوكس.</p><p dir="RTL">&bull; سيكلوسبورين: يستخدم بعد عملية نقل الأعضاء. قد تزداد لديك الآثار الجانبية للسكلوسبورين أثناء تناوله مع رافلوكس.</p><p dir="RTL">&bull; الأدوية المعروفة بأنها تؤثر على ضربات قلبك: وهذا يشمل الأدوية المستخدمة لضربات القلب الغير منتظمة (مثل كوينيدين والأميودارون)، مضادات الاكتئاب ثلاثية الحلقات (مثل أميتريبتيلين وإيميبرامين)، المضادات الحيوية ماكرولييد (مثل الاريثروميسين، أزيثروميسين وكلاريثروميسين) والأدوية المضادة للذهان.</p><p dir="RTL">&bull; بربينسيد (يستخدم لعلاج النقرس) وسيميتيدين (يستخدم لعلاج القرحة وحرقة المعدة).</p><p dir="RTL"><strong>لا تتناول رافلوكس في نفس الوقت مع الأدوية التالية. يجب</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>رافلوكس</strong><strong> </strong><strong>إما</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>ساعتين</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>بعد</strong><strong> </strong><strong>ساعتين</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذه الأدوية</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull;أقراص الحديد &nbsp;(لعلاج الأنيميا) ، العلاج بالفيتامينات المتعددة، أو المستحضرات الأخرى التي تحتوي على المغنيسيوم، الألومينيوم، الحديد أو الزنك.</p><p dir="RTL">&bull; مضادات الحموضة التي تحتوي على المغنيسيوم أو الألومينيوم (لعلاج الحموضة).</p><p dir="RTL">&bull; سكرلفات &nbsp;(لعلاج القرحة المعدية).</p><p dir="RTL">&bull; ديدانوسين مضاد للفيروسات يستخدم في علاج فيروس نقص المناعة البشرية.</p><p dir="RTL">هذا لأنها تؤثر على طريقة عمل رافلوكس.</p><p dir="RTL"><strong>اختبارات</strong><strong> </strong><strong>تحري</strong><strong> </strong><strong>الأفيونيات</strong><strong> </strong><strong>في</strong><strong> </strong><strong>البول</strong><strong>:</strong></p><p dir="RTL">قد يؤدي استخدام رافلوكس لظهور نتائج ايجابية كاذبة لاختبارات تحري الأفيونيات في البول وهي مسكنات قوية للآلام. يجب أن تخبر الطبيب بأنك تتناول أقراص رافلوكس في حالة ما إذا طلب منك اجراء اختبار البول.</p><p dir="RTL"><strong>اختبارات السل:</strong></p><p dir="RTL">قد يتسبب هذا الدواء في نتائج &quot;سلبية كاذبة&quot; لبعض الاختبارات المستخدمة في المختبر للبحث عن البكتيريا المسببة للسل.</p><p dir="RTL"><strong>تناول رافلوكس مع الطعام والشراب:</strong></p><p dir="RTL">يؤخذ مع أو بدون الطعام، مع شرب الكثير من الماء. أخذ رافلوكس مع عصير البرتقال يمكن أن يؤدي إلى انخفاض مستوى الدواء في الدم.</p><p dir="RTL"><strong>د. الحمل والرضاعة:</strong></p><p dir="RTL">إذا كنت حاملا أو ترضعين رضاعة طبيعية أو تعتقدين أنك ربما تكونين حاملاً أو تخططين للحمل فاستشيري الطبيب أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>ه.</strong><strong> </strong><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong><strong>:</strong></p><p dir="RTL">قد تحدث لك بعض الآثار الجانبية عند تناول هذا الدواء مثل الإحساس بالدوخة، الرغبة في النوم، أو الإحساس بالدوار أو تغير في قدرتك على الإبصار. وقد تؤثر هذه الآثار الجانبية على قدرتك على التركيز وسرعة رد فعلك. وفي حالة حدوث هذه الأعراض لا تقم بالقيادة ولا تقم بأي أعمال تتطلب درجة عالية من الانتباه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ دائما أقراص رافلوكس تماما كما قال لك طبيبك. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&bull; تناول هذا الدواء عن طريق الفم</p><p dir="RTL">&bull; ابتلع الأقراص كاملة مع كوب من الماء</p><p dir="RTL">&bull; يمكن تناول الأقراص أثناء الوجبات أو في أي وقت بين الوجبات</p><p dir="RTL"><strong>احمي بشرتك من أشعة الشمس</strong></p><p dir="RTL">ابتعد عن أشعة الشمس المباشرة أثناء تناول رافلوكس ولمدة يومين بعد التوقف عن أخذه. ويرجع ذلك إلى أن بشرتك ستصبح أكثر حساسية للشمس وقد تؤدي إلى الحروق إذا لم تتخذ الاحتياطات التالية:</p><p dir="RTL">&bull; تأكد من استخدام كريم واقي من الشمس.</p><p dir="RTL">&bull; دائما ارتدي قبعة وملابس تغطي ذراعيك والساقين.</p><p dir="RTL">&bull; تجنب أسرّة التشمس.</p><p dir="RTL"><strong>كم يجب أن تأخذ</strong></p><p dir="RTL">&bull; سوف يقرر طبيبك عدد أقراص رافلوكس التي يجب عليك تناولها</p><p dir="RTL">&bull; تعتمد الجرعة على نوع العدوى لديك ومكانها في الجسم.</p><p dir="RTL">&bull; تعتمد مدة العلاج على مدى خطورة العدوى.</p><p dir="RTL">&bull; إذا كنت تشعر أن تأثير الدواء ضعيف جدا أو قوي، لا تغير الجرعة بنفسك، ولكن اسأل طبيبك.</p><p dir="RTL"><strong>البالغين وكبار السن الذين لا يعانون من مشاكل في وظائف الكلى:</strong></p><p dir="RTL"><strong>التهاب الجيوب الأنفية:</strong></p><p dir="RTL">&bull; قرصين من 250 ملجم مرة واحدة يومياً.</p><p dir="RTL">&bull; 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL">&bull; 750 ملجم، مرة واحدة يومياً.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الالتهاب الرئوي:</strong></p><p dir="RTL">&bull; قرصين من 250 ملجم، مرة أو مرتين يومياً.</p><p dir="RTL">&bull; 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL">&bull; 750 ملجم، مرة واحدة يومياً.<strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى الرئتين، في الأشخاص الذين يعانون من مشاكل في التنفس على المدى الطويل:</strong></p><p dir="RTL">&bull; قرصين من 250 ملجم، مرة واحدة يومياً.</p><p dir="RTL">&bull; قرص واحد من 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>عدوى المسالك البولية أو التهاب الحويضة والكلية الحاد:</strong></p><p dir="RTL">&bull; 750 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>التهاب البروستاتا البكتيري المزمن:</strong></p><p dir="RTL">&bull; 500 ملجم، مرة واحدة يومياً.</p><p dir="RTL"><strong>التهاب الجلد وتحت الجلد البكتيري، بما في ذلك العضلات:</strong></p><p dir="RTL">&bull; قرصين من 250 ملجم، مرة أو مرتين يومياً.</p><p dir="RTL">&bull; قرص واحد من 500 ملجم، مرة أو مرتين يومياً.</p><p dir="RTL"><strong>البالغين الذين يعانون من مشاكل في الكلى:</strong></p><p dir="RTL">&bull; قد يحتاج طبيبك إلى إعطائك جرعة أقل.</p><p dir="RTL"><strong>الأطفال والمراهقين:</strong></p><p dir="RTL">&bull; يجب عدم إعطاء هذا الدواء للأطفال أو المراهقين دون سن 18 سنة.</p><p dir="RTL">وذلك لأن الأطفال هم أكثر عرضة للحصول على مشاكل العظام، المفاصل أو الأوتار مثل الألم أو التورم أثناء تناول رافلوكس.</p><p dir="RTL"><strong>أ. </strong><strong>&nbsp;</strong><strong>إذا تناولت رافلوكس بكمية أكبر من مما ينبغي: </strong></p><p dir="RTL">إذا تناولت عدداً من أقراص رافلوكس أكثر من الموصوف لك، استشر الطبيب أو الجأ الى مساعدة طبية في الحال. خذ معك علبة الدواء لكي يتمكن الطبيب من معرفة الدواء الذي تناولته. قد تحدث بعض التأثيرات التالية: تشنجات أو نوبات عصبية، الاحساس بالارتباك، دوخة، نقص الوعي والإدراك، ومشاكل في القلب تؤدي إلى اضطراب في ضربات القلب والإحساس بالغثيان.</p><p dir="RTL"><strong>ب. </strong><strong>&nbsp;</strong><strong>إذا نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>رافلوكس</strong><strong>:</strong></p><p dir="RTL">إذا نسيت تناول جرعة من أقراص رافلوكس، تناول الجرعة حالما تذكرت الا إذا كان موعد الجرعة الي تليها قد أوشك. في هذه الحالة، لا تأخذ جرعة مضاعفة للتعويض عن الجرعة التي أغفلتها.</p><p dir="RTL"><strong>ج. </strong><strong>&nbsp;</strong><strong>إذا توقفت عن أخذ رافلوكس</strong><strong>:</strong></p><p dir="RTL">لا تتوقف عن تناول أقراص رافلوكس لمجرد الاحساس بتحسن حالتك، فمن المهم أن تتم مدة العلاج لك من قبل الطبيب المعالج. ان التوقف عن تناول رافلوكس قبل نهاية المدة المحددة قد يؤدي الى تعرضك للإصابة بالمرض مرة أخرى وقد تسوء حالتك أو قد تتكون للبكتيريا المسببة للمرض مناعة ضد العلاج.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كانت</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أسئلة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>استفسارات</strong><strong> </strong><strong>أخرى،</strong><strong> </strong><strong>استشر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية يمكن أن يسبب رافلوكس أعراضا جانبية. إلا أنها قد لا تحدث مع جميع المرضى. وتكون معظم هذه الأعراض خفيفة إلى متوسطة وتختفي بعد فترة قصيرة.</p><p dir="RTL"><strong>توقف عن تناول رافلوكس وتوجه لزيارة الطبيب في الحال إذا ظهر عليك أي من الأعراض التالية:</strong></p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; الإسهال المائي الذي قد يحتوي على دم، وربما مع تشنجات المعدة وارتفاع درجة الحرارة. يمكن أن تكون هذه علامات على وجود مشكلة حادة في الأمعاء.</p><p dir="RTL">&bull; ألم والتهاب في الأوتار أو الأربطة، مما قد يؤدي إلى تمزق وتر أخيل أو العرقوب وهو الأكثر تأثراً في معظم الأحيان.</p><p dir="RTL">&bull; تشنجات.</p><p dir="RTL"><strong>نادرة جدا (قد تؤثر على ما يصل إلى 1 من كل 10،000 شخص)</strong></p><p dir="RTL">&bull; لديك تفاعلات تحسسية. قد تتضمن العلامات: طفح جلدي، مشاكل في الابتلاع أو التنفس أو تورم في الشفاه، الوجه، الحلق أو اللسان.</p><p dir="RTL">&bull; وخز، ألم أو تنميل. قد تكون هذه علامات على شيء يسمى &quot;الاعتلال العصبي&quot;.</p><p dir="RTL"><strong>أُخرى</strong>:</p><p dir="RTL">&bull; الطفح الجلدي الحاد الذي قد يشمل تقرحات أو تقشير الجلد حول الشفاه والعينين والفم والأنف والأعضاء التناسلية.</p><p dir="RTL">&bull; فقدان الشهية، واصفرار الجلد والعينين، والبول داكن اللون، والحكة، أو ألم في البطن. قد تكون هذه علامات على مشاكل في الكبد التي قد تشمل فشل في الكبد.</p><p dir="RTL">إذا لاحظت ضعف في النظر أو إذا كان لديك أي اضطرابات أخرى في العين أثناء تناول رافلوكس استشر أخصائي العيون على الفور.</p><p dir="RTL"><strong>أخبر طبيبك إذا كان أي من الآثار الجانبية التالية يزداد خطورة أو يستمر لفترة أطول من بضعة أيام:</strong></p><p dir="RTL"><strong>شائع (قد يؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; مشاكل في النوم.</p><p dir="RTL">&bull; صداع، والشعور بالدوار.</p><p dir="RTL">&bull; الشعور بالمرض (الغثيان والقيء) والإسهال.</p><p dir="RTL">&bull; زيادة في مستوى بعض إنزيمات الكبد في الدم.</p><p dir="RTL"><strong>غير شائع (قد يؤثر على شخص واحد من كل 100 شخص)</strong></p><p dir="RTL">&bull; تغير في عدد البكتيريا أو الفطريات، والعدوى عن طريق الفطريات كالمبيضات، والتي قد تحتاج إلى علاج.</p><p dir="RTL">&bull; تغير عدد خلايا الدم البيضاء التي تظهر في بعض نتائج اختبارات الدم مثل الحمضات.</p><p dir="RTL">&bull; الشعور بالقلق، الارتباك، العصبية، النعاس، الارتجاف، أو الدوران (الدوخة).</p><p dir="RTL">&bull; ضيق في التنفس.</p><p dir="RTL">&bull; التغير في حاسة التذوق، وفقدان الشهية، واضطراب في المعدة أو عسر الهضم، والشعور بانتفاخ البطن أو الإمساك.</p><p dir="RTL">&bull; الحكة والطفح الجلدي، أو الشرى، وفرط التعرق.</p><p dir="RTL">&bull; ألم في المفاصل أو العضلات.</p><p dir="RTL">&bull; اختبارات الدم قد تظهر نتائج غير صحيحة بسبب مشاكل في الكبد (زيادة البيليروبين) أو الكلى (زيادة الكرياتينين).</p><p dir="RTL">&bull; الشعور بالتعب.<strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; كدمات ونزيف بسهولة وذلك بسبب انخفاض في عدد الصفائح الدموية.</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم البيضاء.</p><p dir="RTL">&bull; فرط الاستجابة المناعية.</p><p dir="RTL">&bull; انخفاض مستوى السكر في الدم وهذا أمر مهم للأشخاص الذين يعانون من مرض السكري.</p><p dir="RTL">&bull; الهلوسة، جنون العظمة، وتغيير في رأيك والأفكار (تفاعلات نفسية) مع خطر وجود أفكار انتحارية.</p><p dir="RTL">&bull; الشعور بالاكتئاب، والمشاكل العقلية، والشعور بالهيجان، أو الكوابيس.</p><p dir="RTL">&bull; الشعور بالوخز في يديك وقدميك (تنميل).</p><p dir="RTL">&bull; طنين الأذن أو عدم وضوح الرؤية.</p><p dir="RTL">&bull; عدم انتظام دقات القلب أو انخفاض ضغط الدم.</p><p dir="RTL">&bull; ضعف العضلات. وهذا مهم في الأشخاص الذين يعانون من الوهن العضلي الوبيل (مرض نادر في الجهاز العصبي).</p><p dir="RTL">&bull; مشاكل في الكلى والفشل الكلوي العرضي الذي قد يكون بسبب رد فعل كلوي تحسسي يسمى التهاب الكلية الخلالي.</p><p dir="RTL">&bull; الحمى.</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى:</strong></p><p dir="RTL">&bull; فقر الدم: وقد تؤدي هذه الحالة إلى تغير لون الجلد إلى اللون الشاحب أو الأصفر وذلك بسبب الضرر الذي يصيب خلايا الدم الحمراء وانخفاض عدد جميع خلايا الدم.</p><p dir="RTL">&bull; الحمى والتهاب الحلق والشعور بالتعب. قد يكون هذا بسبب انخفاض في عدد خلايا الدم البيضاء (ندرة المحببات).</p><p dir="RTL">&bull; هبوط حاد في الدورة الدموية (الصدمة التحسسية).</p><p dir="RTL">&bull; زيادة مستوى السكر في الدم أو خفض مستوى السكر في الدم مما يؤدي إلى غيبوبة (غيبوبة سكر). وهذا أمر مهم للأشخاص الذين يعانون من مرض السكري.</p><p dir="RTL">&bull; تغير رائحة الأشياء أو فقدان حاسة الشم أو التذوق.</p><p dir="RTL">&bull; مشاكل في الحركة والمشي (خلل الحركة، اضطرابات خارج السبيل الهرمي).</p><p dir="RTL">&bull; فقدان مؤقت للوعي (إغماء).</p><p dir="RTL">&bull; فقدان مؤقت للرؤية.</p><p dir="RTL">&bull; ضعف أو فقدان السمع.</p><p dir="RTL">&bull; عدم انتظام ضربات القلب بشكل سريع، واضطراب في نظم القلب غير المنتظمة الذي قد يشمل توقف القلب، وتغيير ضربات القلب (يسمى &quot;إطالة فترة QT&quot;، الذي قد يُرى من خلال تخطيط القلب، والنشاط الكهربائي للقلب).</p><p dir="RTL">&bull; صعوبة في التنفس أو الصفير (ضيق شديد في التنفس).</p><p dir="RTL">&bull; ردود فعل الرئة التحسسية.</p><p dir="RTL">&bull; التهاب البنكرياس.</p><p dir="RTL">&bull; التهاب الكبد.</p><p dir="RTL">&bull; زيادة حساسية بشرتك للشمس والأشعة فوق البنفسجية.</p><p dir="RTL">&bull; التهاب الأوعية الدموية بسبب رد فعل تحسسي من الدواء (التهاب الأوعية الدموية).</p><p dir="RTL">&bull; التهاب الأنسجة داخل الفم.</p><p dir="RTL">&bull; تمزق وتدمير العضلات (الانحلال الروماتزمي).</p><p dir="RTL">&bull; احمرار وتورم المفاصل (التهاب المفاصل).</p><p dir="RTL">&bull; آلام وتشمل آلام بالظهر والصدر والأطراف.</p><p dir="RTL">&bull; نوبات البورفيريا في الناس الذين يعانون بالفعل من مرض البورفيريا (مرض نادر جدا في التمثيل الغذائي).</p><p dir="RTL">&bull; الصداع المستمر مع أو بدون عدم وضوح في الرؤية (ارتفاع ضغط الدم داخل الجمجمة الحميد).</p><p dir="RTL"><strong>في حال زادت الأعراض الجانبية سوء، أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، قم بالتواصل مع الطبيب أو الصيدلي.</strong></p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">فاكس: 7662-205-11-966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات:</p><p dir="RTL">هاتف: 2038222-11-966+&nbsp; &nbsp; تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">الهاتف المجاني:&nbsp;&nbsp; &nbsp;8002490000</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp; &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa/npc&nbsp;&nbsp;</p><p dir="RTL"><strong>&bull;</strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; قم بتخزين هذا الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull; احفظ أقراص رافلوكس المغلفة غشائيًا في العلبة الأصلية وفي مكان جاف.</p><p dir="RTL">&bull; لا تتناول هذا الدواء بعد تاريخ الانتهاء الموضح على الكرتون والقصدير بعد كلمة Exp. &nbsp;يشير تاريخ انتهاء الصلاحية إلى آخر يوم من هذا الشهر.</p><p dir="RTL">&bull; لا يُخزن في درجة حرارة أكثر من 30 درجة مئوية.</p><p dir="RTL">&bull; يجب عدم التخلص من الأدوية في مياه الصرف أو مع مخلفات المنزل. أسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">رافلوكس 250 ملجم، 500 ملجم و750 ملجم يحتوي على المادة الفعالة ليفوفلوكساسين هيميهيدرات. كل قرص يحتوي على 250 ملجم، 500 ملجم أو 750 ملجم من الليفوفلوكساسين.</p><p dir="RTL">المكونات الأخرى هي: سيليلوز دقيق البلورات، هيدروكسي بروبايل ميثيل سيليلوز، كروسبوفيدون، كروسكارميلوز الصوديوم، ستيرات المغنيسيوم وأوبادري أبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; <u>رافلوكس</u><u> 250</u> ملجم أقراص مغلفة غشائيا لونها أبيض إلى أبيض فاتح على شكل أقراص بيضاوية وتحمل على جهة واحدة علامة C7&quot;&quot;</p><p dir="RTL">&bull; <u>رافلوكس</u><u> 500</u> ملجم أقراص مغلفة غشائيا لونها أبيض إلى أبيض فاتح على شكل أقراص بيضاوية وتحمل على جهة واحدة علامة &quot;C5&quot;</p><p dir="RTL">&nbsp;&bull;رافلوكس<u> 750</u> ملجم أقراص مغلفة غشائيا لونها أبيض إلى أبيض فاتح على شكل أقراص بيضاوية وتحمل على جهة واحدة علامة &quot;C6&quot;</p><p dir="RTL">رافلوكس 250, 500 و750 ملجم متوفر في ظروف تحتوي على 5 أقراص مغلفة غشائيًا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة مصنع الرأي للصناعات الدوائية(ذ.م.م.)</strong></p><p dir="RTL">الوادي- 2، شارع المعتصم بالله الفاطمي</p><p dir="RTL">صندوق بريد: 9224 جدة - ٢١٤١٣ المملكة العربية السعودية</p><p dir="RTL">تلفون:&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;122888949 966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p dir="RTL">فاكس:&nbsp; &nbsp; &nbsp; 122888014 966+&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p dir="RTL">ايميل:&nbsp; Info@alraipharma.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Raflox 500 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Raflox contains levofloxacin hemihydrate corresponding to 500 mg of levofloxacin. 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet 
White to off-white, Caplet shape film coated tablet embossed with C7 on one side and plain on other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Raflox 500 mg Film-Coated Tablets</p><p>Indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):</p><p>&bull;&nbsp; Acute bacterial sinusitis</p><p>&bull;&nbsp; Acute exacerbations of chronic bronchitis</p><p>&bull;&nbsp; Community-acquired pneumonia</p><p>&bull;&nbsp; Complicated skin and soft tissue infections</p><p>For the above-mentioned infections, Raflox Tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.</p><p>&bull; Pyelonephritis and complicated urinary tract infections (see section 4.4)</p><p>&bull;&nbsp; Chronic bacterial prostatitis</p><p>&bull;&nbsp; Uncomplicated cystitis (see section 4.4)</p><p>&bull;&nbsp; Inhalation Anthrax: postexposure prophylaxis and curative treatment (see section 4.4)</p><p>Raflox Tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Raflox Tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the sensitivity of the presumed causative pathogen</p><p>Treatment Time</p><p>The duration of therapy varies according to the course of the disease (see table below). As with antibiotic therapy in general, administration of Raflox Tablets should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacterial eradication has been obtained.</p><p>The following dose recommendations can be given for Raflox Tablets:</p><p><u>Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Daily dose regimen (according to severity)</strong></p></td><td><p><strong>Duration of treatment </strong><em>(according to severity)</em></p></td></tr><tr><td><p>Acute bacterial sinusitis</p></td><td><p>500 mg once daily</p></td><td><p>10 - 14 days</p></td></tr><tr><td><p>Acute bacterial exacerbations of chronic bronchitis</p></td><td><p>500 mg once daily</p></td><td><p>7 - 10 days</p></td></tr><tr><td><p>Community-acquired pneumonia</p></td><td><p>500 mg once or twice daily</p></td><td><p>7 - 14 days</p></td></tr><tr><td><p>Pyelonephritis</p></td><td><p>500 mg once daily</p></td><td><p>7 - 10 days</p></td></tr><tr><td><p>Complicated urinary tract infections</p></td><td><p>500 mg once daily</p></td><td><p>7 - 14 days</p></td></tr><tr><td><p>Uncomplicated cystitis</p></td><td><p>250 mg once daily</p></td><td><p>3 days</p></td></tr><tr><td><p>Chronic bacterial prostatitis</p></td><td><p>500 mg once daily</p></td><td><p>28 days</p></td></tr><tr><td><p>Complicated Skin and soft tissue infections</p></td><td><p>500 mg once or twice daily</p></td><td><p>7 - 14 days</p></td></tr><tr><td><p>Inhalation Anthrax</p></td><td><p>500 mg once daily</p></td><td><p>8 weeks</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p><strong><em><u>Special Populations</u> </em></strong></p><p><u>&nbsp;Impaired Renal Function (Creatinine Clearance &le; 50 ml/min)</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="3"><p><strong>Creatinine clearance</strong></p></td><td><p><strong>Dosage regimen</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>250 mg/24 h</p></td><td><p>500 mg/24 h</p></td><td><p>500 mg/12 h</p></td></tr><tr><td><p>First dose: 250 mg</p></td><td><p>First dose: 500 mg</p></td><td><p>First dose: 500 mg</p></td></tr><tr><td><p>50-20 ml/min</p></td><td><p>Then:125 mg/24h</p></td><td><p>Then: 250 mg/24 h</p></td><td><p>Then:250 mg/12 h</p></td></tr><tr><td><p>19-10 ml/min</p></td><td><p>Then: 125 mg/48 h</p></td><td><p>Then: 125 mg/24 h</p></td><td><p>Then:125 mg/12 h</p></td></tr><tr><td><p>&lt; 10 ml/min (including haemodialysis and CAPD)<sup>1</sup></p></td><td><p>Then: 125 mg/48 h</p></td><td><p>Then: 125 mg/24 h</p></td><td><p>Then:125 mg/24 h</p></td></tr></tbody></table><p><sup>1 </sup>No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).&nbsp;</p><p><u>Impaired Liver Function</u></p><p>No adjustment of dosage is required since Raflox is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p><p><u>Elderly Population</u></p><p>No adjustment of dosage is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p><p><u>Paediatric Population</u></p><p>Raflox contraindicated in children and growing adolescents (see section 4.3).&nbsp;</p><p><u>Method of Administration</u></p><p>Raflox Tablets should be swallowed without crushing and with sufficient amount of liquid. The tablets may be taken during meals or between meals. Raflox Tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine <em>(only didanosine formulations with aluminium or magnesium containing buffering agents), </em>and sucralfate administration since reduction of absorption can occur (see section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Raflox Tablets must not be used: 
•in patients hypersensitive to Raflox or other quinolones or to any of the excipients listed in section 6.1, 
• in patients with epilepsy, 
•in patients with history of tendon disorders related to fluoroquinolone administration, 
•in children or growing adolescents 
•during pregnancy, 
•in breast-feeding women. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Methicillin-Resistant Staphylococcus Aureus (MRSA)</u></p><p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore Raflox is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to Raflox (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).</p><p>Raflox may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.</p><p>Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.</p><p>Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><u>Tendinitis and Tendon Rupture</u></p><p>Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with Raflox and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of these patients is therefore necessary if they are prescribed Levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with Raflox must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see sections 4.3 and 4.8).</p><p><u>Clostridium Difficile-Associated Disease</u></p><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with Raflox (including several weeks after treatment), may be symptomatic of <em>Clostridium difficile</em>-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is</p><p>pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, Raflox Tablets should be stopped immediately and appropriate treatment initiated without delay (e.g. oral metronidazole or vancomycin). Medicinal products inhibiting the peristalsis are contraindicated in this clinical situation.</p><p><u>Patients Predisposed To Seizures</u></p><p>Quinolones may lower the seizure threshold and may trigger seizures. Raflox is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures, or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with Raflox should be discontinued.</p><p><u>Patients with G-6- Phosphate Dehydrogenase Deficiency</u></p><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if Raflox has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p><u>Patients with Renal Impairment</u></p><p>Since Raflox is excreted mainly by the kidneys, the dose of Raflox Tablets should be adjusted in patients with renal impairment. (see section 4.2).</p><p><u>Hypersensitivity Reactions</u></p><p>Raflox can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><p><u>Severe Bullous Reactions</u></p><p>Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with Raflox (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur</p><p><u>Dysglycaemia</u></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p><u>Prevention of Photosensitisation</u></p><p>Photosensitisation has been reported with Raflox (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.</p><p><u>Patients Treated With Vitamin K Antagonists</u></p><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with Raflox in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).</p><p><u>Psychotic Reactions</u></p><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of Raflox (see section 4.8). In the event that the patient develops these reactions, Raflox should be discontinued and appropriate measures instituted. Caution is recommended if Raflox is to be used in psychotic patients or in patients with a history of psychiatric disease.</p><p><u>QT Interval Prolongation</u></p><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&bull;Congenital long QT syndrome</p><p>&bull;Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>&bull;Uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)</p><p>&bull;Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations. (see section 4.2 <em>Elderly</em>, section 4.5, section 4.8, section 4.9)</p><p><u>Peripheral Neuropathy</u></p><p>Sensory or sensorimotor peripheral neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Raflox should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.</p><p><u>Hepatobiliary Disorders</u></p><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><p><u>Exacerbation of Myasthenia Gravis</u></p><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Raflox not recommended in patients with a known history of myasthenia gravis.</p><p><u>Vision Disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><u>Superinfection</u></p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p>Interference with laboratory tests</p><p>In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Raflox may inhibit the growth of <em>Mycobacterium tuberculosis </em>and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of Other Medicinal Products on Raflox</p><p><u>Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine </u></p><p>Raflox absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) are administered concomitantly with Raflox Tablets. Concurrent administration of fluoroquinolones with multi- vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents) </em>should not be taken 2 hours before or after Raflox Tablets administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.</p><p><u>Sucralfate</u></p><p>The bioavailability of Raflox Tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and Raflox Tablets, it is best to administer sucralfate 2 hours after the Raflox Tablets administration (see section 4.2).</p><p><u>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</u></p><p>No pharmacokinetic interactions of Raflox were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Raflox concentrations were about 13 % higher in the presence of fenbufen than when administered alone.</p><p><u>Probenecid and cimetidine</u></p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of Raflox was reduced by cimetidine (24 %) and probenecid (34 %). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.</p><p>Caution should be exercised when Raflox is coadministered with drugs that effect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p><u>Other Relevant Information</u></p><p>Clinical pharmacology studies have shown that the pharmacokinetics of Raflox were not affected to any clinically relevant extent when Raflox was administered together with the following drugs:</p><p>&bull;Calcium carbonate</p><p>&bull;Digoxin</p><p>&bull;Glibenclamide</p><p>&bull;Ranitidine.</p><p><u>Effect of Raflox on Other Medicinal Products</u></p><p><u>Ciclosporin</u></p><p>The half-life of ciclosporin was increased by 33 % when coadministered with levofloxacin.</p><p><u>Vitamin K antagonists</u></p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with Raflox in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).</p><p><u>Drugs known to prolong the QT interval</u></p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotic). (See section 4.4 QT interval prolongation).</p><p><u>Other<strong> </strong>relevant information</u></p><p><u>In a pharmacokinetic interaction study, Raflox did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that Raflox is not a CYP1A2 inhibitor.</u> <u>Other forms of interactions</u></p><p><u>Meals</u></p><p>There is no clinically relevant interaction with food. Raflox Tablets may therefore be administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited amount of data with respect to the use of Raflox in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Raflox must not be used in pregnant women (see sections 4.3 and 5.3).</p><p><u>Breast-Feeding</u></p><p>Raflox tablets are contraindicated in breast-feeding women. There is insufficient information on the excretion of Raflox in human milk; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight- bearing cartilage of the growing organism, Raflox must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><p><u>Fertility</u></p><p>Raflox caused no impairment of fertility or reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, and visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.</p><p>Frequencies are defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100, &lt; 1/10), uncommon (&ge; 1/1,000, &lt; 1/100), rare (&ge; 1/10,000, &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="width:109px"><p><strong>System Organ Class</strong></p></td><td style="width:94px"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10 )</strong></p></td><td style="width:77px"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1,000 to &lt; 1/100)</strong></p></td><td><p><strong>Rare (&ge; 1/10,000 to &lt; 1/1,000)</strong></p></td><td><p><strong>Not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="width:109px"><p>Infections</p><p>And</p><p>Infestations</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:77px"><p>Fungal infection including Candida infection</p><p>Pathogen resistance</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:109px"><p>Blood And</p><p>Lymphatic System Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:77px"><p>Leukopenia Eosinophilia</p></td><td><p>Thrombocytopenia Neutropenia</p></td><td><p>Pancytopenia</p><p>Agranulocytosis</p><p>Haemolytic anaemia</p></td></tr><tr><td style="width:109px"><p>Immune</p><p>System</p><p>Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:77px"><p>&nbsp;</p></td><td><p>Angioedema</p><p>Hypersensitivity</p><p>(see section 4.4)</p></td><td><p>Anaphylactic shock<sup>a</sup></p><p>Anaphylactoid shock <sup>a</sup></p><p>(see section 4.4)</p></td></tr><tr><td style="width:109px"><p>Metabolism And</p><p>Nutrition</p><p>Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:77px"><p>Anorexia</p></td><td><p>Hypoglycaemia</p><p>particularly in diabetic patients (see section</p><p>4.4)</p></td><td><p>Hyperglycaemia</p><p>Hypoglycaemic coma</p><p>(see section 4.4)</p></td></tr><tr><td style="width:109px"><p>Psychiatric Disorders</p></td><td style="width:94px"><p>Insomnia</p></td><td style="width:77px"><p>Anxiety</p><p>Confusional state</p><p>Nervousness</p></td><td><p>Psychotic reactions (with e.g. hallucination, paranoia) Depression</p><p>Agitation</p></td><td><p>Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="width:109px"><p>&nbsp;</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>&nbsp;</p></td><td style="width:144px"><p>Abnormal dreams Nightmares</p></td><td style="width:250px"><p>&nbsp;</p></td></tr><tr><td style="width:109px"><p>Nervous System Disorders</p></td><td style="width:94px"><p>Headache Dizziness</p></td><td style="width:93px"><p>Somnolence</p><p>Tremor</p><p>Dysgeusia</p></td><td style="width:144px"><p>Convulsion (see sections 4.3 and 4.4)</p><p>Paraesthesia</p></td><td style="width:250px"><p>Peripheral sensory neuropathy (see section 4.4) Peripheral sensory motor neuropathy (see section 4.4)</p><p>Parosmia including anosmia Dyskinesia Extrapyramidal disorder Ageusia</p><p>Syncope</p><p>Benign intracranial hypertension</p></td></tr><tr><td style="width:109px"><p>Eye Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>&nbsp;</p></td><td style="width:144px"><p>Visual disturbances such as blurred vision (see section 4.4)</p></td><td style="width:250px"><p>Transient vision loss (see section 4.4)</p></td></tr><tr><td style="width:109px"><p>Ear and Labyrinth Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>Vertigo</p></td><td style="width:144px"><p>Tinnitus</p></td><td style="width:250px"><p>Hearing loss</p><p>Hearing impaired</p></td></tr><tr><td style="width:109px"><p>Cardiac Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>&nbsp;</p></td><td style="width:144px"><p>Tachycardia, Palpitation</p></td><td style="width:250px"><p>Ventricular tachycardia, which may result in cardiac</p><p>arrest Ventricular arrhythmia and torsade de pointes</p><p>(reported predominantly in patients with risk factors of QT prolongation), electrocardiogram QT prolonged (see sections 4.4 and 4.9)</p></td></tr><tr><td style="width:109px"><p>Vascular Disorders</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>&nbsp;</p></td><td style="width:144px"><p>Hypotension</p></td><td style="width:250px"><p>&nbsp;</p></td></tr><tr><td style="width:109px"><p>Respiratory, Thoracic</p></td><td style="width:94px"><p>&nbsp;</p></td><td style="width:93px"><p>Dyspnoea</p></td><td style="width:144px"><p>&nbsp;</p></td><td style="width:250px"><p>Bronchospasm</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="width:105px"><p>And Mediastinal Disorders</p></td><td style="width:90px"><p>&nbsp;</p></td><td style="width:104px"><p>&nbsp;</p></td><td style="width:140px"><p>&nbsp;</p></td><td style="width:253px"><p>Pneumonitis allergic</p></td></tr><tr><td style="width:105px"><p>Gastro- Intestinal Disorders</p></td><td style="width:90px"><p>Diarrhoea</p><p>Vomiting</p><p>Nausea</p></td><td style="width:104px"><p>Abdominal pain</p><p>Dyspepsia Flatulence</p><p>Constipation</p></td><td style="width:140px"><p>&nbsp;</p></td><td style="width:253px"><p>Diarrhoea &ndash; haemorrhagic which in very rare cases may be indicative of enterocolitis,</p><p>including pseudomembranous</p><p>colitis (see section</p><p>4.4)</p><p>Pancreatitis</p></td></tr><tr><td style="width:105px"><p>Hepatobiliary Disorders</p></td><td style="width:90px"><p>Hepatic enzyme increased (ALT/AST,</p><p>alkaline phosphatase,</p><p>GGT)</p></td><td style="width:104px"><p>Blood bilirubin increased</p></td><td style="width:140px"><p>&nbsp;</p></td><td style="width:253px"><p>Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases</p><p>(see section 4.4)</p><p>Hepatitis</p></td></tr><tr><td style="width:105px"><p>Skin and</p><p>Subcutaneous Tissue Disorders <sup>B</sup></p></td><td style="width:90px"><p>&nbsp;</p></td><td style="width:104px"><p>Rash</p><p>Pruritus Urticaria</p></td><td style="width:140px"><p>&nbsp;</p></td><td style="width:253px"><p>Toxic epidermal</p><p>necrolysis Stevens-Johnson</p></td></tr><tr><td style="width:105px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="width:90px"><p>&nbsp;</p></td><td style="width:104px"><p>Hyperhidrosis</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="width:140px"><p>&nbsp;</p></td><td style="width:253px"><p>syndrome</p><p>Erythema multiforme Photosensitivity reaction</p><p>(see section 4.4) Leukocytoclastic</p><p>vasculitis Stomatitis</p></td></tr><tr><td style="width:105px"><p>Musculoskeletal and</p><p>Connective Tissue</p><p>Disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="width:90px"><p>&nbsp;</p></td><td style="width:104px"><p>Arthralgia</p><p>Myalgia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="width:140px"><p>Tendon disorders (see</p><p>sections 4.3 and 4.4)</p><p>including tendinitis</p><p>(e.g. Achilles tendon)</p><p>Muscular weakness</p><p>which may be of</p><p>special importance in patients with</p></td><td style="width:253px"><p>Rhabdomyolysis</p><p>Tendon rupture (e.g.</p><p>Achilles tendon) (see</p><p>sections 4.3 and 4.4)</p><p>Ligament rupture</p><p>Muscle rupture</p><p>Arthritis</p><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="width:110px"><p>&nbsp;</p></td><td style="width:95px"><p>&nbsp;</p></td><td style="width:103px"><p>&nbsp;</p></td><td style="width:137px"><p>myasthenia gravis (see section 4.4 )</p></td><td style="width:245px"><p>&nbsp;</p></td></tr><tr><td style="width:110px"><p>Renal and Urinary Disorders</p></td><td style="width:95px"><p>&nbsp;</p></td><td style="width:103px"><p>Blood creatinine increased</p></td><td style="width:137px"><p>Renal failure acute (e.g. due to interstitial nephritis)</p></td><td style="width:245px"><p>&nbsp;</p></td></tr><tr><td style="width:110px"><p>General Disorders and</p><p>Administration</p><p>Site Conditions</p></td><td style="width:95px"><p>&nbsp;</p></td><td style="width:103px"><p>Asthenia</p></td><td style="width:137px"><p>Pyrexia</p></td><td style="width:245px"><p>Pain (including pain in back, chest, and extremities)</p></td></tr></tbody></table><p><sup>a </sup>Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose</p><p><sup>b </sup>Mucocutaneous reactions may sometimes occur even after the first dose</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&bull; Attacks of porphyria in patients with porphyria.</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>To report any side effect(s): </strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><strong><u>Other GCC States:</u></strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdosage of Raflox are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing Raflox from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Antiifectives for systemic use &ndash; Antibacterials for systemic use &ndash; Quinolone antibasterials &ndash; Fluoroquinolones</p><p>ATC code: J01MA12</p><p>Raflox is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic drug substance ofloxacin.</p><p><em>Mechanism of action </em></p><p>As a fluoroquinolone antibacterial agent, Raflox acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p><p><em>PK/PD relationship </em></p><p>The degree of the bactericidal activity of Raflox depends on the ratio of the maximum concentration in serum (C<sub>max</sub>) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p><p><em>Mechanism(s) of resisance </em></p><p>Resistance to Raflox is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also affect susceptibility to levofloxacin.</p><p><em>Cross</em>-resistance between Raflox and other fluoroquinolones <em>is observed. </em>Due to the mechanism of action, there is generally no cross-resistance between Raflox and other classes of antibacterial agents.</p><p><u>Breakpoints</u></p><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/L).</p><p><em>EUCAST clinical MIC breakpoints for Raflox (version 2.0, 2012-01-01): </em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriacae</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Pseudomonas spp.</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Acinetobacter spp.</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus spp.</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>S.pneumoniae <sup>1</sup></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus A,B,C,G</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>H.influenzae <sup>2,</sup> <sup>3</sup> M.catarrhalis <sup>3</sup></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints <sup>4</sup></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr></tbody></table><p><sup>1.&nbsp;&nbsp; </sup>The breakpoints for Raflox relate to high dose therapy.</p><p><sup>2.&nbsp;&nbsp; </sup>Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with <em>H. influenzae</em>.</p><p><sup>3.&nbsp;&nbsp; </sup>Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.</p><p><sup>4.&nbsp;&nbsp; </sup>Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2.</p><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p><strong><u>Commonly Susceptible Species</u> </strong></p><p>&nbsp;<strong><u>Aerobic Gram-Positive Bacteria&nbsp;</u></strong></p><p>Bacillus anthracis</p><p>Staphylococcus aureus methicillin-susceptible</p><p>Staphylococcus saprophyticus</p><p>Streptococci, group C and G</p><p>Streptococcus agalactiae</p><p>Streptococcus pneumoniae</p><p>Streptococcus pyogenes</p><p><strong><u>Aerobic Gram- Negative Bacteria</u></strong></p><p>Eikenella corrodens</p><p>Haemophilus influenzae</p><p>Haemophilus para-influenzae</p><p>Klebsiella oxytoca</p><p>Moraxella catarrhalis</p><p>Pasteurella multocida</p><p>Proteus vulgaris</p><p>Providencia rettgeri</p><p><strong><u>Anaerobic Bacteria</u> </strong></p><p>Peptostreptococcus</p><p><u><strong>Other</strong></u></p><p>Chlamydophila pneumoniae</p><p>Chlamydophila psittaci</p><p>Chlamydia trachomatis</p><p>Legionella pneumophila</p><p>Mycoplasma pneumoniae</p><p>Mycoplasma hominis</p><p>Ureaplasma urealyticum</p><p><u><strong>Species For Which Acquired Resistance May Be A Problem &nbsp;Aerobic Gram-Positive Bacteria</strong></u></p><p>Enterococcus faecalis</p><p>Staphylococcus aureus methicillin-resistant<sup>#</sup></p><p>Coagulase negative Staphylococcus spp</p><p><strong><u>Aerobic Gram- Negative Bacteria</u></strong></p><p>Acinetobacter baumannii</p><p>Citrobacter freundii</p><p>Enterobacter aerogenes</p><p>Enterobacter cloacae</p><p>Escherichia coli</p><p>Klebsiella pneumoniae</p><p>Morganella morganii</p><p>Proteus mirabilis</p><p>Providencia stuartii</p><p>Pseudomonas aeruginosa</p><p>Serratia marcescens</p><p><strong><u>Anaerobic Bacteria</u> </strong></p><p>Bacteroides fragilis</p><p>Inherently Resistant Strains</p><p>Aerobic Gram-Positive Bacteria</p><p>Enterococcus faecium</p><p># Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Orally administered Raflox is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1- 2 h. The absolute bioavailability is 99- 100 %.</p><p>Food has little effect on the absorption of levofloxacin.</p><p>Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><p>Distribution</p><p>Approximately 30 - 40 % of Raflox is bound to serum protein. The mean volume of distribution of Raflox is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p><em><u>Penetration into Tissues and Body Fluids:</u> </em></p><p>Raflox has been shown to penetrate<em> </em>into bronchial mucosa<em>, </em>epithelial lining fluid, alveolar macrophages, lung tissue<em>, skin (</em>blister fluid), prostatic tissue and urine. However<em>, </em>Raflox has poor penetration intro cerebro- spinal fluid.</p><p><u>Biotransformation</u></p><p>Raflox is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N- oxide. These metabolites account for &lt; 5 % of the dose excreted in urine. Raflox is stereochemically stable and does not undergo chiral inversion.</p><p>Elimination</p><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t<sub>&frac12;</sub>: 6 - 8 h). Excretion is primarily by the renal route &gt; 85 % of the administered dose).</p><p>The mean apparent total body clearance of Raflox following a 500 mg single dose was 175 +/-29.2 ml/min.</p><p>There are no major differences in the pharmacokinetics of Raflox following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><p><em><u>Linearity</u> </em></p><p>Raflox obeys linear pharmacokinetics over a range of 50 to 1000 mg.</p><p>Special Populations</p><p><u>Subjects with renal insufficiency</u></p><p>The pharmacokinetics of Raflox affected by renal impairment. With decreasing renal function, renal elimination and clearance decreased, and elimination half-lives increased as shown in the table below:</p><p>Pharmacokinetics in renal insufficiency following single oral 500 mg dose</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Cl<sub>cr</sub> [ml/min]</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>20 - 49</p></td><td style="vertical-align:top"><p>50 - 80</p></td></tr><tr><td style="vertical-align:top"><p>Cl<sub>R</sub> [ml/min]</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub> [h]</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p><u><em>Elderly Subjects</em></u><em> </em></p><p>There are no significant differences in Raflox kinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</p><p><u><em>Gender Differences</em></u><em> </em></p><p>Separate analysis for male and female subjects showed small to marginal gender differences in</p><p>Raflox pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Raflox caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.</p><p>Raflox did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. <em>In vivo </em>tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed Raflox to have phototoxic activity only at very high doses. Raflox did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenity study.</p><p>In common with other fluoroquinolones, Raflox showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:281px"><tbody><tr><td style="vertical-align:top"><p>1.</p></td><td style="vertical-align:top"><p>Microcrystalline Cellulose 102</p></td></tr><tr><td style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Hypromellose E15</p></td></tr><tr><td style="vertical-align:top"><p>3.</p></td><td><p>Crospovidone</p></td></tr><tr><td style="vertical-align:top"><p>4.</p></td><td><p>Croscarmellose sodium</p></td></tr><tr><td style="vertical-align:top"><p>5.</p></td><td><p>Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>6.</p></td><td style="vertical-align:top"><p>Opadry II (Y-1-7000) White</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p><p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Raflox is available in blister packs containing five film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrai Pharmaceutical Industries Co. (L.L.C.)
Al Wadi - 2, Almu’tasem Bellah Al Fatemy Street
P.O.Box: 9224 Jeddah - 21413 Kingdom of Saudi Arabia
Tel: 		+966 12 2888949
Fax: 	+966 12 2889014
E-mail: 	info@alraipharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>